AbbVie | ABBV

Stock Price
162.12
Daily Change
2.02 1.26%
Monthly
-0.20%
Yearly
18.46%
Q2 Forecast
159.72
Peers Price Chg Day Year Date
Eisai 7,080.00 115.00 1.65% -27.76% Jun/05
AbbVie 162.12 2.02 1.26% 18.46% Jun/04
Abbott 103.16 0.54 0.53% -0.58% Jun/04
ALKERMES 23.65 -0.41 -1.68% -19.72% Jun/04
Amgen 307.39 0.41 0.13% 38.54% Jun/04
AstraZeneca 12,498.00 94.00 0.76% 5.63% Jun/05
Biogen 233.71 4.18 1.82% -22.65% Jun/04
BioMarin Pharmaceutical 79.09 2.68 3.51% -13.78% Jun/04
Bristol-Myers Squibb 41.83 -0.02 -0.05% -36.60% Jun/04
Gilead Sciences 64.15 0.73 1.15% -17.46% Jun/04
GlaxoSmithKline 1,649.50 34.50 2.14% 18.55% Jun/05
J&J 147.84 0.08 0.05% -6.62% Jun/04
Eli Lilly 832.20 3.77 0.45% 87.32% Jun/04
Medtronic 83.00 1.18 1.44% -0.87% Jun/04
Merck 128.78 0.15 0.12% 13.85% Jun/04
Neurocrine Biosciences 133.48 -6.44 -4.60% 42.21% Jun/04
Novartis 94.05 1.32 1.42% 3.90% Jun/05
Pacira 30.52 -0.37 -1.20% -20.83% Jun/04
Pfizer 29.50 0.17 0.58% -23.67% Jun/04
Perrigo 27.18 -0.45 -1.63% -17.71% Jun/04
Ultragenyx Pharmaceutical 40.92 -0.21 -0.51% -20.16% Jun/04
Regeneron Pharmaceuticals 993.29 5.21 0.53% 32.39% Jun/04
Roche Holding 237.10 2.90 1.24% -18.84% Jun/05
Sanofi 90.86 0.59 0.65% -5.72% Jun/05
UCB 129.50 1.75 1.37% 54.20% Jun/05
United Therapeutics 273.19 -3.07 -1.11% 24.81% Jun/04
Vertex Pharmaceuticals 474.95 4.89 1.04% 42.02% Jun/04
Zoetis 171.99 -0.43 -0.25% 0.51% Jun/04

Indexes Price Day Year Date
US500 5304 7.94 0.15% 23.82% Jun/05

AbbVie traded at $162.12 this Tuesday June 4th, increasing $2.02 or 1.26 percent since the previous trading session. Looking back, over the last four weeks, AbbVie gained 0.20 percent. Over the last 12 months, its price rose by 18.46 percent. Looking ahead, we forecast AbbVie to be priced at 159.72 by the end of this quarter and at 156.81 in one year, according to Trading Economics global macro models projections and analysts expectations.

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. AbbVie offers its products in various therapeutic categories, including Immunology products, which include Humira, Skyrizi and Rinvoq; Oncology products consists of Imbruvica and Venclexta; Aesthetics products include Botox Cosmetic, Juvederm Collection and other aesthetics; Neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; Eye care products consists of Lumigan, Alphagan and Restasis ; Women's health products incudes Lo Loestrin, Orilissa and other women's health; and Other key products, which includes Mavyret, Creon, Lupron, Linzess and Synthroid. The Company's products are sold worldwide directly to wholesalers, distributors, government agencies, health care facilities and independent retailers from AbbVie-owned distribution centers and public warehouses.